Published: 20 March 2018
Author(s): Daniele Cattaneo, Umberto Gianelli, Paola Bianchi, Agostino Cortelezzi, Alessandra Iurlo
Issue: March 2018
Section: Letter to the Editor

In BCR-ABL1-negative myeloproliferative neoplasms (MPNs) thrombo-hemorrhagic complications represent the most common cause of morbidity and mortality. In particular, the reported overall incidence of major thrombotic events ranges from 1.75 to 5.5% events patient-years according to the specific MPN subtype [1]. Arterial thrombotic events, including ischemic stroke, acute coronary syndrome and peripheral arterial thrombosis, account for the majority of these complications (60–70%); accidents in the venous compartment, i.e.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.